PSS
MCID: SYS005
MIFTS: 61

Systemic Scleroderma (PSS) malady

Categories: Rare diseases, Skin diseases, Immune diseases, Genetic diseases, Neuronal diseases, Nephrological diseases, Respiratory diseases, Bone diseases

Aliases & Classifications for Systemic Scleroderma

Aliases & Descriptions for Systemic Scleroderma:

Name: Systemic Scleroderma 38 12 50 25 14 69
Scleroderma 12 50 41 14 69
Systemic Sclerosis 12 50 25 14
Progressive Systemic Sclerosis 12 50
Scleroderma, Systemic 50 42
Scleroderma, Familial Progressive 69
Familial Progressive Scleroderma 25
Progressive Scleroderma 25
Scleroderma, Localized 42
Scleroderma Syndrome 12
Diffuse Scleroderma 69
Scleroderma Disease 52
Dermatosclerosis 12
Pss 12

Classifications:



Summaries for Systemic Scleroderma

NIH Rare Diseases : 50 scleroderma is an autoimmune disorder that may involve changes in the skin, blood vessels, muscles, and internal organs. there are two main types: localized scleroderma, which affects only the skin; and systemic scleroderma, which affects the blood vessels and internal organs, as well as the skin. these two main types also have sub-types. localized scleroderma subtypes include:linear scleroderma morphea systemic scleroderma subtypes include:diffuse cutaneous systemic sclerosis limited cutaneous systemic sclerosis (which includes crest syndrome) limited systemic sclerosis the underlying cause of scleroderma is currently unknown; however, some scientists suspect it may be related to a buildup of collagen in the skin and other organs due to an abnormal immune system response. some cases of scleroderma are induced by environmental factors or occur in association with other underlying disorders such as rheumatoid arthritis, lupus or sjogren syndrome. there is no cure, but various treatments may relieve symptoms. last updated: 9/12/2016

MalaCards based summary : Systemic Scleroderma, also known as scleroderma, is related to diffuse scleroderma and lupus erythematosus, and has symptoms including arthralgia, fatigue and myalgia. An important gene associated with Systemic Scleroderma is CTGF (Connective Tissue Growth Factor), and among its related pathways/superpathways are Glucocorticoid receptor regulatory network and Photodynamic therapy-induced NF-kB survival signaling. The drugs Bosentan and Tadalafil have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and lung, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Disease Ontology : 12 A scleroderma that is characterized by fibrosis (or hardening) of the skin and major organs, as well as vascular alterations, and autoantibodies.

Genetics Home Reference : 25 Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. The word "scleroderma" means hard skin in Greek, and the condition is characterized by the buildup of scar tissue (fibrosis) in the skin and other organs. The condition is also called systemic sclerosis because the fibrosis can affect organs other than the skin. Fibrosis is due to the excess production of a tough protein called collagen, which normally strengthens and supports connective tissues throughout the body.

MedlinePlus : 41 scleroderma means hard skin. it is a group of diseases that cause abnormal growth of connective tissue. connective tissue is the material inside your body that gives your tissues their shape and helps keep them strong. in scleroderma, the tissue gets hard or thick. it can cause swelling or pain in your muscles and joints. symptoms of scleroderma include calcium deposits in connective tissues raynaud's phenomenon, a narrowing of blood vessels in the hands or feet swelling of the esophagus, the tube between your throat and stomach thick, tight skin on your fingers red spots on your hands and face no one knows what causes scleroderma. it is more common in women. it can be mild or severe. doctors diagnose scleroderma using your medical history, a physical exam, lab tests, and a skin biopsy. there is no cure, but various treatments can control symptoms and complications. nih: national institute of arthritis and musculoskeletal and skin diseases

Wikipedia : 71 Systemic scleroderma, also called diffuse scleroderma or systemic sclerosis, is an autoimmune disease of... more...

Related Diseases for Systemic Scleroderma

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive Localized Scleroderma

Diseases related to Systemic Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 133)
id Related Disease Score Top Affiliating Genes
1 diffuse scleroderma 31.1 CENPB CTGF EXOSC10 SNRNP70 TOP1
2 lupus erythematosus 30.3 ACE CRP SELP
3 calcinosis 30.0 ACE CD40LG CRP CTGF TGFB1
4 limb ischemia 29.5 ACE CRP SELP
5 diffuse cutaneous systemic sclerosis 11.6
6 potocki-shaffer syndrome 11.6
7 peeling skin syndrome 1 11.6
8 peeling skin syndrome 2 11.5
9 peeling skin syndrome 3 11.5
10 scleroderma, familial progressive 11.1
11 limited scleroderma 11.1
12 adrenoleukodystrophy 10.9
13 reynolds syndrome 10.9
14 generalized peeling skin syndrome 10.9
15 stiff skin syndrome 10.8
16 psychosocial short stature 10.8
17 crest syndrome 10.8
18 peeling skin syndrome 10.7
19 tuberculous pneumothorax 10.4 ACE CD40LG
20 geleophysic dysplasia 2 10.3 CTGF FBN1 TGFB1
21 agammaglobulinemia 6 10.3 ACE CTGF TGFB1
22 hereditary night blindness 10.3 CTGF SELE TGFB1
23 dermatomycosis 10.3 CD40LG CRP SELE
24 hypertrichosis of eyelid 10.3 ACE CTGF TGFB1
25 israeli tick typhus 10.3 CD40LG IFNG SELE
26 hypolipoproteinemia 10.3 ACE CD40LG CRP
27 pulmonary valve insufficiency 10.3 ACE CTGF TGFB1
28 radial hypoplasia, triphalangeal thumbs and hypospadias 10.3 CD40LG SELE TGFB1
29 hypertrophic elongation of cervix 10.3 ACE CD40LG CRP
30 chronic thromboembolic pulmonary hypertension 10.3 IFNG SELE TGFB1
31 hyperlucent lung 10.3 CD40LG CRP IFNG
32 plummer's disease 10.3 CD40LG CRP IFNG
33 deafness, autosomal recessive 79 10.3 ACE CRP FBN1
34 strawberry gallbladder 10.3 CRP IFNG TGFB1
35 acute laryngitis 10.3 CD40LG PRL TGFB1
36 skin conditions 10.3 ACE SFTPD TGFB1
37 ischemic optic neuropathy 10.3 ACE CRP SELP
38 systolic heart failure 10.3 ACE CRP TGFB1
39 focal dystonia 10.3 ACE CRP SELP
40 stiff-person syndrome 10.3 CD40LG CRP IFNG
41 optic nerve neoplasm 10.3 ACE CRP SELE
42 mixed germ cell-sex cord neoplasm 10.3 ACE CD40LG TGFB1
43 endobronchial lipoma 10.3 ACE CD40LG MLN
44 schizotypal personality disorder 10.3 ACE CRP HRH2
45 retinal ischemia 10.2 ACE IFNG SFTPD
46 intra-abdominal lymph node mast cell malignancy 10.2 ACE CRP SELP
47 sertoli-leydig cell tumor 10.2 CD40LG SELE SELP
48 myiasis 10.2 CD40LG CRP IFNG TGFB1
49 malignant neoplasm of acoustic nerve 10.2 CTGF IFNG SFTPD TGFB1
50 pemphigus vulgaris, familial 10.2 CD40LG CRP SELE

Comorbidity relations with Systemic Scleroderma via Phenotypic Disease Network (PDN): (show all 13)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Esophagitis
Heart Disease Hypothyroidism
Localized Scleroderma Peripheral Vascular Disease
Postinflammatory Pulmonary Fibrosis Protein-Energy Malnutrition
Pulmonary Hypertension, Familial Primary, 1, with or Without Hht Raynaud Disease
Systemic Lupus Erythematosus

Graphical network of the top 20 diseases related to Systemic Scleroderma:



Diseases related to Systemic Scleroderma

Symptoms & Phenotypes for Systemic Scleroderma

Human phenotypes related to Systemic Scleroderma:

32 (show top 50) (show all 80)
id Description HPO Frequency HPO Source Accession
1 arthralgia 32 HP:0002829
2 fatigue 32 HP:0012378
3 myalgia 32 HP:0003326
4 cachexia 32 HP:0004326
5 edema 32 HP:0000969
6 seizures 32 HP:0001250
7 angina pectoris 32 HP:0001681
8 chest pain 32 HP:0100749
9 abdominal pain 32 HP:0002027
10 nausea and vomiting 32 HP:0002017
11 muscle weakness 32 HP:0001324
12 dry skin 32 HP:0000958
13 joint dislocation 32 HP:0001373
14 respiratory insufficiency 32 HP:0002093
15 bowel incontinence 32 HP:0002607
16 behavioral abnormality 32 HP:0000708
17 arthritis 32 HP:0001369
18 carious teeth 32 HP:0000670
19 malabsorption 32 HP:0002024
20 gastroesophageal reflux 32 HP:0002020
21 feeding difficulties in infancy 32 HP:0008872
22 renal insufficiency 32 HP:0000083
23 nephropathy 32 HP:0000112
24 cranial nerve paralysis 32 HP:0006824
25 subcutaneous nodule 32 HP:0001482
26 pulmonary fibrosis 32 HP:0002206
27 acrocyanosis 32 HP:0001063
28 hypertrophic cardiomyopathy 32 HP:0001639
29 arrhythmia 32 HP:0011675
30 skeletal muscle atrophy 32 HP:0003202
31 myocardial infarction 32 HP:0001658
32 hyperkeratosis 32 HP:0000962
33 peripheral neuropathy 32 HP:0009830
34 congestive heart failure 32 HP:0001635
35 lack of skin elasticity 32 HP:0100679
36 decreased nerve conduction velocity 32 HP:0000762
37 atypical scarring of skin 32 HP:0000987
38 autoimmunity 32 HP:0002960
39 cirrhosis 32 HP:0001394
40 skin ulcer 32 HP:0200042
41 hypopigmented skin patches 32 HP:0001053
42 migraine 32 HP:0002076
43 memory impairment 32 HP:0002354
44 gastroparesis 32 HP:0002578
45 heart block 32 HP:0012722
46 hematuria 32 HP:0000790
47 mucosal telangiectasiae 32 HP:0100579
48 xerostomia 32 HP:0000217
49 irregular hyperpigmentation 32 HP:0007400
50 narrow mouth 32 HP:0000160

UMLS symptoms related to Systemic Scleroderma:


exanthema, pruritus, hidebound skin

MGI Mouse Phenotypes related to Systemic Scleroderma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 HRH2 IFNG PRL SELE SELP SFTPD
2 endocrine/exocrine gland MP:0005379 10.02 ACE CD40LG CENPB FBN1 HRH2 IFNG
3 immune system MP:0005387 10 ACE CD40LG CRP FBN1 IFNG PRL
4 mortality/aging MP:0010768 9.77 TGFB1 TOP1 TPO ACE CD40LG CENPB
5 integument MP:0010771 9.76 CD40LG CTGF FBN1 IFNG PRL SELE
6 respiratory system MP:0005388 9.17 IFNG SELE SELP SFTPD TGFB1 CTGF

Drugs & Therapeutics for Systemic Scleroderma

Drugs for Systemic Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 253)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bosentan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 147536-97-8 104865
2
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2 171596-29-5 110635
3
Cilostazol Approved Phase 4 73963-72-1 2754
4 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1
5 Endothelin Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1
6 Vaccines Phase 4
7 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
8 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1
9 Vasodilator Agents Phase 4,Phase 2,Phase 3,Early Phase 1
10 Autonomic Agents Phase 4,Phase 2,Phase 3,Early Phase 1
11 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Early Phase 1
12 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
13 Platelet Aggregation Inhibitors Phase 4,Phase 2,Phase 3
14 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15 Respiratory System Agents Phase 4,Phase 2,Phase 3
16 Sildenafil Citrate Phase 4,Phase 3,Phase 2,Early Phase 1 171599-83-0
17 Anti-Asthmatic Agents Phase 4
18 Bronchodilator Agents Phase 4
19 Fibrinolytic Agents Phase 4,Phase 2,Phase 3
20 Phosphodiesterase 3 Inhibitors Phase 4
21 Liver Extracts Phase 4
22 Citrate Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1
23
Citric Acid Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 77-92-9 311
24 Acidophilus Nutraceutical Phase 4,Phase 3
25 Omega 3 Fatty Acid Nutraceutical Phase 4
26
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
27
Iloprost Approved, Investigational Phase 2, Phase 3 78919-13-8 6443959
28
Nitroglycerin Approved, Investigational Phase 3,Phase 2 55-63-0 4510
29
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
30
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Early Phase 1 83-43-2 6741
31
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Early Phase 1 50-24-8 5755
32
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
33
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
34
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
35
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
36
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
37
Macitentan Approved Phase 3 441798-33-0
38
Domperidone Approved, Investigational, Vet_approved Phase 3 57808-66-9 3151
39
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
40
Omeprazole Approved, Investigational, Vet_approved Phase 3 73590-58-6 4594
41
Acetylcholine Approved Phase 3,Phase 2 51-84-3 187
42
Methocarbamol Approved, Vet_approved Phase 3,Phase 2 532-03-6 4107
43
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
44
Mesna Approved Phase 3,Phase 1 3375-50-6 598
45
Fludarabine Approved Phase 3,Phase 1,Phase 2 21679-14-1, 75607-67-9 30751
46
Vidarabine Approved Phase 3,Phase 1,Phase 2 24356-66-9 32326 21704
47
Nintedanib Approved Phase 3 656247-17-5 56843413
48
Lactulose Approved Phase 3 4618-18-2 11333
49
Prednisone Approved, Vet_approved Phase 3,Phase 1 53-03-2 5865
50
Bupivacaine Approved, Investigational Phase 2, Phase 3 2180-92-9, 38396-39-3 2474

Interventional clinical trials:

(show top 50) (show all 314)
id Name Status NCT ID Phase
1 The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis Unknown status NCT02480335 Phase 4
2 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
3 Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan Unknown status NCT01051960 Phase 4
4 A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis Unknown status NCT01042158 Phase 4
5 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
6 Bosentan in Systemic Sclerosis Completed NCT01395732 Phase 4
7 Pulmonary Artery Remodelling With Bosentan Completed NCT00595049 Phase 4
8 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4
9 To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis Recruiting NCT03053739 Phase 4
10 Intraoperative ICG for Systemic Sclerosis Not yet recruiting NCT03155464 Phase 4
11 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
12 Comparison of Esophageal and Anorectal Manometry Catheters Terminated NCT00204763 Phase 4
13 Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis Withdrawn NCT01497743 Phase 4
14 High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis Unknown status NCT00428883 Phase 2, Phase 3
15 Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis Unknown status NCT02302352 Phase 3
16 Platelet Gel in Systemic Sclerosis Unknown status NCT00463125 Phase 2, Phase 3
17 Serial Night Time Position Splint on Systemic Sclerosis Unknown status NCT01586663 Phase 3
18 Early Diagnosis of Pulmonary Hypertension in Patients With Inflammatory Rheumatic Connective Tissue Diseases Unknown status NCT01387035 Phase 3
19 A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3
20 Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Unknown status NCT00934427 Phase 3
21 Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis Completed NCT00348296 Phase 3
22 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3
23 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3
24 Effectiveness and Safety of Lidocaine for Scleroderma Completed NCT00740285 Phase 2, Phase 3
25 Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients Completed NCT01474109 Phase 3
26 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3
27 Gastroesophageal Reflux Treatment in Scleroderma Completed NCT01878526 Phase 3
28 Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma Completed NCT00070590 Phase 2, Phase 3
29 Scleroderma Lung Disease Completed NCT00004563 Phase 3
30 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3
31 Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma Completed NCT00704665 Phase 3
32 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3
33 Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma Completed NCT00077584 Phase 3
34 Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension Completed NCT00984932 Phase 3
35 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3
36 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3
37 Bosentan in Digital Ulcers Completed NCT00319696 Phase 3
38 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Completed NCT01532869 Phase 3
39 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3
40 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3
41 Open-label Study With Bosentan in Interstitial Lung Disease Completed NCT00319033 Phase 2, Phase 3
42 Imiquimod in Children With Plaque Morphea Completed NCT00147771 Phase 3
43 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3
44 Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3
45 Lab Study of MQX-503 in Treatment of Raynaud's Completed NCT00253331 Phase 2, Phase 3
46 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3
47 Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3
48 "As Required" Oral Sildenafil in Raynaud's Phenomenon Completed NCT02050360 Phase 2, Phase 3
49 Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension Completed NCT00080457 Phase 3
50 Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial Recruiting NCT01445821 Phase 3

Search NIH Clinical Center for Systemic Scleroderma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Systemic Scleroderma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Systemic Scleroderma:
Hematopoietic stem cells for systemic sclerosis

Cochrane evidence based reviews: scleroderma, localized

Genetic Tests for Systemic Scleroderma

Anatomical Context for Systemic Scleroderma

MalaCards organs/tissues related to Systemic Scleroderma:

39
Skin, Heart, Lung, Testes, Kidney, Skeletal Muscle, T Cells

Publications for Systemic Scleroderma

Articles related to Systemic Scleroderma:

(show top 50) (show all 218)
id Title Authors Year
1
Platelet-rich gel for the adjuvant treatment of wound healing of transposed flap for arteriovenous fistula in systemic scleroderma. ( 28058708 )
2017
2
Fixed Implant Supported Rehabilitation of Partially Edentulous Posterior Maxilla in a Patient With Systemic Scleroderma: A Case Report. ( 26671839 )
2016
3
Caring for the Patient With Limited Systemic Scleroderma. ( 26814000 )
2016
4
A neoteric multidrug combination: novel approach to limited cutaneous systemic scleroderma involving the face. ( 27033280 )
2016
5
Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. ( 27455250 )
2016
6
Distinguishing between limited systemic scleroderma-associated pseudo-obstruction and peritoneal dissemination. ( 26943389 )
2015
7
Unilateral acquired Brown's syndrome in systemic scleroderma: An unusual cause for diplopia. ( 26669341 )
2015
8
Pro- and antiangiogenic markers in patients with pulmonary complications of systemic scleroderma. ( 25447676 )
2015
9
Interstitial Lung Disease in Systemic Scleroderma, Complicated with Bilateral Pulmonary Aspergilloma: An Unusual Association. ( 26816937 )
2015
10
Fat embolism syndrome: an autopsy-proven case involving a patient on dialysis and systemic scleroderma. ( 24526839 )
2014
11
An unusual cause of acute kidney injury due to oxalate nephropathy in systemic scleroderma. ( 25500295 )
2014
12
Comparison of a new, modified lung ultrasonography technique with high-resolution CT in the diagnosis of the alveolo-interstitial syndrome of systemic scleroderma. ( 24567921 )
2014
13
Oesophageal stenosis dilatation through retrograde trans-gastrostomal approach in a patient with systemic scleroderma. ( 24956348 )
2014
14
Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. ( 23910613 )
2013
15
Pulmonary artery hypertension associated with systemic scleroderma: correlation among lung pulmonary blood volume, lung perfusion single photon emission computed tomography, and chest computed tomography images. ( 23283858 )
2013
16
Antiphospholipid antibodies and systemic scleroderma. ( 24385841 )
2013
17
Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms. ( 22843057 )
2013
18
Case of lung carcinoma revealed by vulvar metastasis associated with systemic scleroderma and literature review. ( 24416551 )
2013
19
Clinicopathological study of 81 cases of localized and systemic scleroderma. ( 22620486 )
2013
20
Systemic scleroderma associated with ulnar nerve entrapment at the elbow. ( 24343497 )
2013
21
Antiphospholipid antibodies and systemic scleroderma. ( 24385750 )
2013
22
MicroRNA array analysis of microRNAs related to systemic scleroderma. ( 21052672 )
2012
23
Cardiac arrhythmia as a side effect of ketanserin therapy in a patient with systemic scleroderma. ( 22507478 )
2012
24
Drug compliance in patients with systemic scleroderma. ( 22875701 )
2012
25
Bone density in Moroccan women with systemic scleroderma and its relationships with disease-related parameters and vitamin D status. ( 21947376 )
2012
26
Determinants of disability, quality of life and depression in dermatological patients with systemic scleroderma. ( 21916888 )
2012
27
The optimal management of patients with systemic scleroderma and coronary artery disease. ( 22774391 )
2012
28
Cardiovascular assessment of asymptomatic patients with juvenile-onset localized and systemic scleroderma: 10 years prospective observation. ( 22103465 )
2012
29
Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features. ( 22018289 )
2011
30
Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. ( 21097800 )
2011
31
Hearing loss in diffuse cutaneous systemic scleroderma. ( 21916804 )
2011
32
Fingertip calcinosis cutis in an incomplete limited-type systemic scleroderma. ( 21708515 )
2011
33
Study about the association between anticardiolipin antibodies and peripheral vascular phenomena in patients suffering from systemic scleroderma. ( 20676482 )
2010
34
Vitamin D deficiency in a cohort of patients with systemic scleroderma from the south of Spain. ( 20516041 )
2010
35
Type 1 diabetes mellitus, celiac disease, systemic lupus erythematosus and systemic scleroderma in a 15-year-old girl. ( 19506880 )
2010
36
[Antibodies to enzymes of purine metabolism as a factor of gastrointestinal tract lesions in systemic scleroderma]. ( 19551958 )
2009
37
Surgical result of critical limb ischemia due to tibial arterial occlusion in patients with systemic scleroderma. ( 19223137 )
2009
38
Electrocardiographic evaluation in patients with systemic scleroderma and without clinically evident heart disease. ( 19614636 )
2009
39
Management of cutaneous vascular complications in systemic scleroderma: experience from the German network. ( 18320192 )
2008
40
Systemic scleroderma with moderate to severe mitral regurgitation: unusual three-dimensional echocardiographic features. ( 18273492 )
2008
41
Development of systemic scleroderma in a patient with myelodysplastic syndrome. ( 18779108 )
2008
42
Gastrointestinal symptoms and motility disorders in patients with systemic scleroderma. ( 18304354 )
2008
43
Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity. ( 18158195 )
2008
44
The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. ( 18515867 )
2008
45
Nifedipine effect on red cell rheological properties in patients with systemic scleroderma. ( 17325434 )
2007
46
Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. ( 17848933 )
2007
47
Esophageal damages in systemic scleroderma. ( 17582977 )
2007
48
Platelet activation in patients with systemic scleroderma--pattern and significance. ( 18333373 )
2007
49
Is occupational exposure to solvents associated with an increased risk for developing systemic scleroderma? ( 16817950 )
2006
50
A survey of TCM studies on systemic scleroderma. ( 16817284 )
2006

Variations for Systemic Scleroderma

Expression for Systemic Scleroderma

Search GEO for disease gene expression data for Systemic Scleroderma.

Pathways for Systemic Scleroderma

Pathways related to Systemic Scleroderma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.25 IFNG PRL SELE
2
Show member pathways
10.93 CD40LG IFNG SELE
3 10.71 CD40LG IFNG SELE SELP TGFB1

GO Terms for Systemic Scleroderma

Cellular components related to Systemic Scleroderma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 ACE CD40LG CRP CTGF FBN1 IFNG
2 external side of plasma membrane GO:0009897 9.46 ACE CD40LG IFNG SELP
3 extracellular space GO:0005615 9.36 ACE CD40LG CRP CTGF FBN1 IFNG

Biological processes related to Systemic Scleroderma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.63 CTGF PRL TGFB1
2 inflammatory response GO:0006954 9.55 CD40LG CRP SELE SELP TGFB1
3 leukocyte tethering or rolling GO:0050901 9.43 SELE SELP
4 cellular response to transforming growth factor beta stimulus GO:0071560 9.43 FBN1 SNRNP70 TGFB1
5 negative regulation of interleukin-17 production GO:0032700 9.4 IFNG TGFB1
6 positive regulation of superoxide anion generation GO:0032930 9.37 CRP TGFB1
7 cellular response to insulin-like growth factor stimulus GO:1990314 9.32 FBN1 TGFB1
8 mononuclear cell proliferation GO:0032943 8.96 ACE TGFB1
9 leukocyte cell-cell adhesion GO:0007159 8.8 CD40LG SELE SELP

Molecular functions related to Systemic Scleroderma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sialic acid binding GO:0033691 8.96 SELE SELP
2 oligosaccharide binding GO:0070492 8.62 SELE SELP

Sources for Systemic Scleroderma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....